This site is intended for health professionals only

Published on 16 February 2010

Share this story:
Twitter
LinkedIn

Combined drugs ‘stop cancer growth’

teaser

Patients with advanced kidney cancer could be offered a new first-line treatment after a study showed a specific drugs combination prevented tumours growing with manageable side effects.

The study, published online in The Lancet Oncology, found a “chemo-switch” treatment was more effective for patients with metastatic renal-cell carcinoma (RCC) than using the targeted drug sorafenib alone or with chemotherapy.

Combining treatment options could improve survival rates and response to medication, according to preclinical studies which used a maximum tolerated dose (MTD) chemotherapy (gemcitabine), sorafenib and metronomic chemotherapy, which is frequent low-dose treatments with capecitabine.

The tumour’s rapidly-growing cells are initially killed with the MTD of one chemotherapy drug, which is maintained by a metronomic dose of the second drug. Results showed a rise in progression-free survival (PFS

More frequent, lower doses stop new blood vessels from developing and so prevent cancer growth, and also increases anti-tumour activity by including a targeted inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGFR).

The study authors wrote in The Lancet Oncology Online First: “The combination of sorafenib with MTD gemcitabine and metronomic capecitabine resulted in a clinical benefit rate of over 90%, with an acceptable level of toxicity.”

Copyright Press Association 2010
The Lancet Oncology



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn